Ryan P. McMullin, Ph.D.
Affiliations: | 2008 | Biological Sciences | University of Maryland, Baltimore County, Baltimore, MD, United States |
Area:
Molecular Biology, Cell BiologyGoogle:
"Ryan McMullin"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Charles J. Bieberich | grad student | 2008 | UMBC | |
| (Transcriptional regulation of the prostate-restricted gene Hoxb13.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Efstathiou E, Davis JW, Pisters L, et al. (2019) Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. European Urology |
| Babayan A, Alawi M, Gormley M, et al. (2017) Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. Oncotarget. 8: 56066-56080 |
| Lam HM, McMullin R, Nguyen H, et al. (2016) Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| McMullin R, Gupta H, Rajpurohit Y, et al. (2016) Abstract 3074: Addition of ARN509 and docetaxel, alone or in combination, to castration demonstrates improved efficacy and heterogeneity of molecular response in prostate cancer patient-derived xenografts Cancer Research. 76: 3074-3074 |
| Hubbard GK, Mutton LN, Khalili M, et al. (2015) Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Research |
| Efstathiou E, Li W, Gormley M, et al. (2015) Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. Journal of Clinical Oncology. 33: 5005-5005 |
| Lam H, McMullin R, Nguyen HM, et al. (2015) Abstract 4313: Abiraterone acetate (AA) treatment of prostate cancer patient-derived xenografts (PDX) demonstrates heterogeneity of responses and identifies potential biomarkers of adaptive resistance Cancer Research. 75: 4313-4313 |
| McMullin RP, Wittner BS, Yang C, et al. (2014) A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Research : Bcr. 16: R25 |
| McMullin RP, Sgroi DC. (2014) The HOXB13:IL17BR biomarker: prognostic for late recurrence and predictive for benefit from endocrine therapy Breast Cancer Management. 3: 155-163 |
| Hubbard GK, Mutton LN, Khalili M, et al. (2013) Abstract 1086: MYC overexpression combined with Pten loss generates genomic instability and rapid metastasis in a new mouse model of lethal prostate adenocarcinoma. Cancer Research. 73: 1086-1086 |